Telitacicept for scleroderma, diffuse

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Apr 2024: Trial registered, NCT06375005
  2. 6 Jan 2025: Trial started, NCT06375005

The trials

NCT06375005: Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

State
Under way
Phase
Phase 2
People
38 planned
Started
6 Jan 2025
Primary completion
6 Jan 2027
Arms
Mycophenolate Mofetil + Telitacicept
Results
None posted
  1. 19 Apr 2024: Trial registered
  2. 6 Jan 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.